{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:43:43Z","timestamp":1784832223062,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Ceftriaxone (CTX) is widely used in pediatric infectious disease treatment, although the diagnostic and therapeutic management of CTX-induced gallbladder pseudolithiasis (PL) remains challenging. In this study, we investigated the occurrence, clinical features, and management of CTX-induced PL in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective case-control study was conducted on 185 pediatric patients receiving CTX at a single center. Data on treatment regimens, gallbladder imaging findings, and serum biochemical parameters post-CTX therapy were analyzed. Patients were classified into PL (<jats:italic>n<\/jats:italic>\u2009=\u200934) and non-PL (<jats:italic>n<\/jats:italic>\u2009=\u2009151) groups based on imaging findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PL was diagnosed in 18.4% of patients treated with CTX, primarily through ultrasound, which revealed hyperechoic material within the gallbladder. Compared with the non-PL group, patients with PL were older and taller, with no significant differences in CTX dosage (<jats:italic>p<\/jats:italic>\u2009=\u20090.915). Patients with PL also had higher rates of digestive and neurological infections (both <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Serum analysis revealed distinct liver and kidney function markers in the PL group, including lower levels of total bile acids, adenosine deaminase, and lactate dehydrogenase, and higher creatinine levels (all <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Discontinuation of CTX led to symptom resolution in most cases, and all cases of PL resolved within three months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The occurrence of PL is not significantly related to CTX dosage. Furthermore, the rate of CTX metabolism and excretion may play a key role in PL development. Overall, the findings demonstrate that ultrasound is an effective tool for monitoring the development of PL in children receiving CTX and that discontinuation of CTX could be an effective treatment for PL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1527014","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:51:19Z","timestamp":1737096679000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical features and outcomes of pseudolithiasis induced by ceftriaxone in Chinese children: a single-center observational study"],"prefix":"10.3389","volume":"13","author":[{"given":"Chen","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Li","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Wei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/0016-5085(90)90486-K","article-title":"Pathogenesis of ceftriaxone-associated biliary sludge. in vitro studies of calcium-ceftriaxone binding and solubility","volume":"99","author":"Shiffman","year":"1990","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/archdischild-2019-317950","article-title":"Safety of ceftriaxone in paediatrics: a systematic review","volume":"105","author":"Zeng","year":"2020","journal-title":"Arch Dis Child"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.anpedi.2013.04.001","article-title":"Gallstones in association with the use of ceftriaxone in children","volume":"80","author":"Rodr\u00edguez Rangel","year":"2014","journal-title":"An Pediatr (Barc)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/0016-5085(90)91029-6","article-title":"Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile","volume":"99","author":"Xia","year":"1990","journal-title":"Gastroenterology"},{"key":"B5","first-page":"50","article-title":"Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children","volume":"19","author":"Kong","year":"1996","journal-title":"Changgeng Yi Xue Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/fcp.12841","article-title":"Effect of ceftriaxone on intestinal transit time","volume":"37","author":"Arpac\u0131k","year":"2023","journal-title":"Fundam Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1620\/tjem.211.285","article-title":"Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases","volume":"211","author":"Araz","year":"2007","journal-title":"Tohoku J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1651-2227.1999.tb01050.x","article-title":"Incidence of ceftriaxone-associated gallbladder pseudolithiasis","volume":"88","author":"Papadopoulou","year":"1999","journal-title":"Acta Paediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1055\/s-2008-1072393","article-title":"Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children","volume":"10","author":"Bonnet","year":"2000","journal-title":"Eur J Pediatr Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1051887","DOI":"10.3389\/fped.2022.1051887","article-title":"Ceftriaxone-induced cholestatic hepatitis in a child: a case report and a review of the literature","volume":"10","author":"Castellazzi","year":"2022","journal-title":"Front Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.2169\/internalmedicine.4672-20","article-title":"Ceftriaxone-associated pseudolithiasis in the gallbladder and bile duct of an elderly patient","volume":"59","author":"Yamabe","year":"2020","journal-title":"Intern Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijantimicag.2004.10.008","article-title":"Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical atients","volume":"25","author":"Ceran","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1177\/147323001003800614","article-title":"Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in Chinese children","volume":"38","author":"Meng","year":"2010","journal-title":"J Int Med Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/fcp.12577","article-title":"Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough?","volume":"35","author":"Cuzzolin","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s11604-019-00893-5","article-title":"Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults","volume":"37","author":"Yoshida","year":"2019","journal-title":"Jpn J Radiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.cmet.2019.11.002","article-title":"Regulation of tumor initiation by the mitochondrial pyruvate carrier","volume":"31","author":"Bensard","year":"2020","journal-title":"Cell Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1021\/acs.chemrev.8b00201","article-title":"Targeting metalloenzymes for therapeutic intervention","volume":"119","author":"Chen","year":"2019","journal-title":"Chem Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ped.12625","article-title":"Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis","volume":"57","author":"Murata","year":"2015","journal-title":"Pediatr Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1757-4749-4-11","article-title":"Inactivation of Bacillus cereus vegetative cells by gastric acid and bile during in vitro gastrointestinal transit","volume":"4","author":"Ceuppens","year":"2012","journal-title":"Gut Pathog"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00228-016-2064-7","article-title":"Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score","volume":"72","author":"Nakaharai","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40264-016-0493-y","article-title":"Antibiotic-induced liver injury in paediatric outpatients: a case-control study in primary care databases","volume":"40","author":"Ferrajolo","year":"2017","journal-title":"Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1186\/s12879-022-07925-y","article-title":"Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose","volume":"22","author":"Mistry","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.nlm.2008.01.003","article-title":"Ceftriaxone rescues hippocampal neurons from excitotoxicity and enhances memory retrieval in chronic hypobaric hypoxia","volume":"89","author":"Hota","year":"2008","journal-title":"Neurobiol Learn Mem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1471-4159.2009.06347.x","article-title":"Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro","volume":"111","author":"Lewerenz","year":"2009","journal-title":"J Neurochem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"118119","DOI":"10.1016\/j.lfs.2020.118119","article-title":"Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging","volume":"258","author":"Hakimizadeh","year":"2020","journal-title":"Life Sci"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1527014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:51:21Z","timestamp":1737096681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1527014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":25,"alternative-id":["10.3389\/fped.2025.1527014"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1527014","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"article-number":"1527014"}}